42 results about "Daytime somnolence" patented technology

Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.

Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.

The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy / activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and / or released.

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.

The invention relates to a traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression. The traditional Chinese medicine has obvious treatment effects on symptoms such as deprementia, chest hypochondriac pain, lassitude, upset irritability, abdominal distension and diarrhea and the like of the liver constraint and spleen deficiency type post-strokedepression, improves spirit and emotions, promotes the recovery of neural functions of stroke patients, and does not have obvious toxic or side effects such as dizziness, hypodynamia, somnolence, drymouth, constipation, hypotension, abnormal liver functions, epilepsy, cardiac arrhythmia, toxicosis and the like. The technical scheme is that: the traditional Chinese medicine is prepared form the following raw materials by weight: 10 to 14g of bupleurum, 9 to 11g of turmeric root-tuber, 10 to 14g of Chinese angelica, 10 to 14g of white paeony root, 13.5 to 16.5g of fried largehead atractylodes rhizome, 9 to 11g of Indian buead, 18 to 22g of codonopsis pilosula, 9 to 11g of tangerine peel, 9 to 11g of bamboo shavings, 13.5 to 16.5g of gardenia, 4.5 to 5.5g of mint and 2.7 to 3.3g of liquoricroot. The traditional Chinese medicine is prepared into decoction by the conventional soaking, decocting and filtering or is prepared by directly blending market-sold single Chinese medicinal formulaparticles. The traditional Chinese medicine has the advantages of high reliability, high safety, high flexibility, no dependence and the like.